Less Ads, More Data, More Tools Register for FREE

AstraZeneca completes acquisition of rights to Activis

Tue, 03rd Mar 2015 07:10

AstraZeneca has completed its acquisition of the rights to Activis' branded respiratory business in the US and Canada.The company paid Activis initial consideration worth $600m as well as an extra $100m for a number of contractual consents and approvals.According to an investor note released on Tuesday, AstraZeneca has also agreed to pay low single-digit royalties above a certain revenue threshold.The acquisition has been made to expand AstraZeneca's global respiratory franchise and build on its acquisition of Almirall's 2014 portfolio by moving the company's development and commercialisation rights into the US for both Tudors Pressair and Duaklir Genuair.

Related Shares

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of no...

10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's lat...

10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but abo...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.